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Abstract
Aims: Over the past decades, the placement of dental implants has become a rou-
tine procedure in the oral rehabilitation of fully and partially edentulous patients.
However, the number of patients/implants affected by peri-implant diseases is
increasing. As there are – in contrast to periodontitis – at present no established
and predictable concepts for the treatment of peri-implantitis, primary prevention
is of key importance. The management of peri-implant mucositis is considered as
a preventive measure for the onset of peri-implantitis. Therefore, the remit of this
working group was to assess the prevalence of peri-implant diseases, as well as
risks for peri-implant mucositis and to evaluate measures for the management of
peri-implant mucositis.
Methods: Discussions were informed by four systematic reviews on the current
epidemiology of peri-implant diseases, on potential risks contributing to the
development of peri-implant mucositis, and on the effect of patient and of profes-
sionally administered measures to manage peri-implant mucositis. This consensus
report is based on the outcomes of these systematic reviews and on the expert
opinion of the participants.
Results: Key findings included: (i) meta-analysis estimated a weighted mean prev-
alence for peri-implant mucositis of 43% (CI: 32–54%) and for peri-implantitis of
22% (CI: 14–30%); (ii) bleeding on probing is considered as key clinical measure
to distinguish between peri-implant health and disease; (iii) lack of regular sup-
portive therapy in patients with peri-implant mucositis was associated with
increased risk for onset of peri-implantitis; (iv) whereas plaque accumulation has
been established as aetiological factor, smoking was identified as modifiable
patient-related and excess cement as local risk indicator for the development of
peri-implant mucositis; (v) patient-administered mechanical plaque control (with
manual or powered toothbrushes) has been shown to be an effective preventive
measure; (vi) professional intervention comprising oral hygiene instructions and
mechanical debridement revealed a reduction in clinical signs of inflammation;
(vii) adjunctive measures (antiseptics, local and systemic antibiotics, air-abrasive
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devices) were not found to improve the efficacy of professionally administered
plaque removal in reducing clinical signs of inflammation.
Conclusions: Consensus was reached on recommendations for patients with den-
tal implants and oral health care professionals with regard to the efficacy of mea-
sures to manage peri-implant mucositis. It was particularly emphasized that
implant placement and prosthetic reconstructions need to allow proper personal
cleaning, diagnosis by probing and professional plaque removal.
Dental implants supporting dental
restorations are part of the oral envir-
onment of a significant proportion of
the population and thus, prevention
of peri-implant diseases should be
part of overall oral health care. There
is great variation regarding the age of
patients treated with dental implants
and the type and extent of implant-
supported restorative procedures.
Definitions of peri-implant dis-
eases were agreed upon at previous
European Workshops on Periodon-
tology (Lindhe & Meyle 2008, Lang
& Berglundh 2011). The key parame-
ter for diagnosis for peri-implant
mucositis is bleeding on gentle prob-
ing (<0.25 N). It is assumed that
peri-implant mucositis is the precur-
sor to peri-implantitis, as is gingivitis
for periodontitis, and that a contin-
uum exists from healthy peri-implant
mucosa to peri-implant mucositis
and to peri-implantitis. Therefore,
prevention of peri-implant diseases
involves the prevention of peri-
implant mucositis and the prevention
of the conversion from peri-implant
mucositis into peri-implantitis by
treatment of existing peri-implant
mucositis (Salvi & Zitzmann 2014).
The remit of this working group
was to assess the current epidemiol-
ogy of peri-implant diseases, poten-
tial risks contributing to the
development of peri-implant mucosi-
tis, and the effect of patient and pro-
fessionally administered measures to
manage peri-implant mucositis. This
consensus report is based on four
systematic reviews and on the expert
opinion of the participants.
Peri-implant Health and Disease –
Current Epidemiology
In a systematic review, the preva-
lence, extent and severity of
peri-implant diseases were assessed
(Derks & Tomasi 2015).
As case definitions varied, the
prevalence (based on subject-level)
of peri-implant mucositis and peri-
implantitis ranged from 19 to 65%
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and from 1 to 47% respectively.
Meta-analysis estimated a weighted
mean prevalence of peri-implant mu-
cositis of 43% (CI: 32–54%) in 1196
patients and 4209 implants. The
weighted mean prevalence of peri-
implantitis was 22% (CI: 14–30%),
estimated in 2131 patients and 8893
implants. Studies were performed in
eight different countries in Europe,
South and North America.
The proportion of patients and
implants with healthy peri-implant
mucosa was not reported and could
not be estimated from the presented
data. Data on extent and severity of
disease were rarely presented. Analy-
sis in the review also revealed a posi-
tive relationship between prevalence
of peri-implantitis and function time
and a negative relationship between
prevalence of peri-implantitis and
threshold for bone loss (i.e. smaller
prevalence data resulted when greater
bone loss was set as threshold).
The systematic review identified a
number of shortcomings in the
included studies. Case definitions
varied significantly. All studies were
based upon convenience samples of
limited sample size and a variation
of follow-up. Estimates of prevalence
and incidence should ideally be made
on randomly selected patient sam-
ples of sufficient size and follow-up
time to ensure accuracy.
What is the best clinical measure to
distinguish between peri-implant health
and disease?
Although bleeding on probing was a
consistently used parameter in the
studies included in the systematic
review, case definitions frequently
applied other parameters (e.g. prob-
ing depth) resulting in inconsistent
distinction between health and dis-
ease. As bleeding on probing is an
indicator for inflammation in the
peri-implant mucosa, standardized
sulcular or pocket probing assess-
ment should be considered as the
current clinical measure to distin-
guish between peri-implant health
and disease.
Is there a need for defining severity and
extent of peri-implant disease?
The present review identified few
reports that presented information
on frequencies of different degrees
of bone loss in peri-implantitis.
Considerations should be given to
the value of such severity indices.
Extent of disease must include pro-
portions of affected implants per
patient in the presence of multiple
implants.
What is the risk for conversion from peri-
implant mucositis to peri-implantitis?
There is emerging evidence on the
patient level from a retrospective
study that the lack of annual sup-
portive therapy in patients diagnosed
with peri-implant mucositis was
associated with increased risk for
conversion of mucositis to peri-im-
plantitis (Costa et al. 2012). After
5 years, 18% of the patients comply-
ing with supportive therapy pre-
sented with peri-implantitis, while
the corresponding proportion in
patients who did not adhere to sup-
portive therapy was 43.9%.
Risk Indicators for Peri-implant
Mucositis
A risk factor is defined as “an envi-
ronmental, behavioural or biological
factor that if present directly increases
the probability of a disease occurring
and, if absent or removed reduces
that probability” (Genco 1996). In
the absence of studies fulfilling the
demands in the assessment of risk fac-
tors, a systematic review evaluated
risk indicators for peri-implant muco-
sitis based on cross-sectional and pre-
clinical in vivo studies (Renvert &
Polyzois 2015). Addressing aetiology,
seven experimental and two cross-
sectional studies demonstrated that
plaque accumulation on implants
resulted in peri-implant mucositis.
The review assessed systemic/patient-
related and local risk indicators for
peri-implant mucositis.
What are the systemic/patient-related risk
indicators for the development of peri-
implant mucositis?
Smoking was identified as an inde-
pendent risk indicator for peri-
implant mucositis. A single study of
limited size indicated that exposure
to radiation therapy was associated
with mucositis. One study identified
diabetes as well as gender to be
risk indicators for mucositis, while
two cross-sectional studies described
function time of implants as a risk
indicator for peri-implant mucositis.
What are the local risk indicators for the
development of peri-implant mucositis?
Results from pre-clinical in vivo stud-
ies failed to demonstrate an effect of
design and surface characteristics of
the trans-mucosal portion of implants
on the development of peri-implant
soft tissue inflammation. The effect of
the dimensions of keratinized tissues
(distance between peri-implant muco-
sal margin and the muco-gingival
junction) on the development of peri-
implant mucositis is inconclusive.
Some evidence exists indicating
that excess cement is a risk indicator
for peri-implant mucositis.
Efficacy of Measures to Manage Peri-
implant Mucositis
It is understood that patient-
administered measures are usually per-
formed in conjunction with profes-
sionally administered plaque removal
procedures. For the purpose of this
workshop, two systematic reviews
were performed to evaluate the two
procedures separately. One study eval-
uated the efficacy of patient-adminis-
tered (Salvi & Ramseier 2015), and
another one the efficacy of profession-
ally administered measures (Schwarz
et al. 2015) for plaque control in
patients with peri-implant mucositis.
What are effective ways to prevent peri-
implant mucositis – “primary
prevention”?
At present, there are no studies
available for the primary prevention
of peri-implant mucositis. This is in
contrast to the primary prevention
of gingivitis, in which documentation
exists for frequency of complete pla-
que removal required to maintain
gingival health (Lang et al. 1973).
What are effective ways of patient-
performed plaque control in the
management of peri-implant mucositis?
In the systematic review on the effi-
cacy of patient-administered mea-
sures, eleven RCTs with a follow-up
from 3 to 24 months were included
(Salvi & Ramseier 2015). Three
major groups of treatment were iden-
tified, i.e. mechanical plaque removal
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by means of manual or powered
toothbrushes, chemical plaque con-
trol by means of adjunctive delivery
of antimicrobials and triclosan-con-
taining toothpastes. According to the
consensus report of the VIII Euro-
pean Workshop (Sanz & Chapple
2012), the endpoint of therapy and
primary outcome should be the reso-
lution of peri-implant mucosal
inflammation (frequency distribution
of resolved lesions) as determined by
the absence of BoP. Although com-
plete resolution following patient-
administered measures was not
always reported, a reduction of clini-
cal signs of inflammation as second-
ary outcome was evident in all
studies. One study reported the per-
centage of implants with complete
resolution of peri-implant mucositis.
Manual brushing with or without
adjunctive chlorhexidine gel was
investigated over 3 months and 38%
of the patients/implants were found
with complete resolution of peri-
implant mucositis (Heitz-Mayfield
et al. 2011).
There were a variety of control
treatments that had been used for
comparison indicating that there is a
lack of an accepted standard of
care. All studies were designed as
parallel arm RCTs and six of 11
had an observation time of 6
months, which is in line with the
recommendations given in a previ-
ous consensus (Sanz & Chapple
2012). Study quality was analysed
according to the Cochrane collabo-
ration tool for assessing the risk of
bias, and only four of the 11 studies
achieved at least 80% of positive
answers. Thus the results should be
interpreted with caution.
What are effective ways of professional
plaque control in the management of peri-
implant mucositis?
In the systematic review on the effi-
cacy of professionally administered
plaque removal, seven RCTs were
included (48.6% revealing high risk
of bias) mainly employing a parallel
group design, and BoP reduction
was defined as the primary outcome.
The definition of peri-implant muco-
sitis was heterogeneous among stud-
ies but commonly included positive
BoP at the respective sites. Case defi-
nitions were not reported in two of
the studies evaluated.
Professional intervention mainly
comprised oral hygiene instructions,
mechanical debridement applying a
variety of different hand or powered
instruments and/or polishing tools
and revealed a reduction in clinical
signs of inflammation, while resolu-
tion of BoP on the subject level was
not achieved.
Adjunctive measures (antiseptics,
local and systemic antibiotics, air-
abrasive devices) were not found to
improve the efficacy of profession-
ally administered plaque removal in
reducing clinical signs of inflamma-
tion.
Is Resolution of Peri-implant
Mucositis Achievable?
Both systematic reviews demonstrated
that resolution of peri-implant mucosi-
tis is possible. However, current data
also indicate that resolution of inflam-
mation was not achieved in all patients.
Experimental peri-implant mucositis
was significantly reversed by profes-
sionally administered plaque removal
and reinstitution of oral hygiene prac-
tices conducted over 3 weeks (Salvi
et al. 2012).
What is the current standard of care for
patient- and professionally administered
plaque control for the management of
peri-implant mucositis?
Patient-administered mechanical pla-
que control is an effective preventive
measure. Chemical plaque control
either by oral rinses or a dentifrice
tested to date had limited adjunctive
effect. Patient-administered mechani-
cal plaque control alone (with man-
ual or powered toothbrush) should
be considered the current standard
of care.
Professionally administered pla-
que control procedures should include
regular (based on the individual
needs) oral hygiene instructions and
mechanical debridement employing
different hand or powered instru-
ments with or without polishing tools.
Limitations of Available Research
Meta-analysis was applied in two of
the reviews presented in this working
group (Derks & Tomasi 2015, Sch-
warz et al. 2015). The group high-
lighted that meta-analytic methods
per se do not always strengthen the
level of the available scientific evi-
dence, but rather facilitate its under-
standing. Recommendations (e.g.
PRISMA, MOOSE) for systematic
reviews including meta-analysis
should be carefully considered.
The reviews identified some limita-
tions of the included studies. For epi-
demiological studies as well as studies
on intervention, the main issues were
(i) the variation in case definition, (ii)
the variation in sampling and sample
size and (iii) the limited follow-up
time. In addition, studies included in
the two reviews on management of
peri-implant mucositis showed varying
risks of bias (according to the Cochra-
ne checklist). A lack of standard con-
trol treatment for mucositis was
apparent. Included studies assessed
efficacy of interventions in highly con-
trolled clinical settings. Such studies
may not allow the evaluation of effec-
tiveness in general populations. Com-
parisons of dichotomous and ordinal
outcome variables were often based on
group averages rather than analysis of
frequency distributions.
Recommendations for Research
In a previous consensus report focus-
ing on quality of reporting (Sanz &
Chapple 2012) recommendations for
future research on epidemiology and
prevention of peri-implant diseases
were given. The present working
group strongly supports these previ-
ous recommendations. For epidemio-
logical studies, establishment of
national/regional implant databases
was advocated. Studies should be
adequately powered, randomly sam-
pled and consider sufficient follow-
up. Risk assessments should include a
multiple-step process and aim at
establishing causality by addressing
criteria such as those proposed by
Hill (1965).
The working group identified the
need for defining and reporting
peri-implant health (e.g. absence of
bleeding on probing) and incidence
of disease from prospective cohort
studies.
For intervention trials, appropriate
endpoints, i.e. resolution of inflamma-
tion at the given site, as well as the lack
of standard control treatment were
identified as critical issues. Therapeutic
measures demonstrating efficacy in
properly designed RCT studies should
be evaluated in field studies. The com-
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parison of clinical parameters should
be based on changes rather than abso-
lute values. Data management should
consider multiple and multi-level logis-
tic regression models to correctly
address binary and ordinal data.
Areas of interest for future
research are as follows:
• Primary prevention of peri-
implant mucositis
• Risk assessment
• Importance of attached/kerati-
nized tissue
• Efficacy of interproximal cleaning
• Further evaluation of adjunctive
measures
• Individualized supportive therapy
Recommendations for Dental
Professionals
According to the present data, peri-
implant diseases are very common.
Therefore, it is imperative for the cli-
nician to examine and evaluate
patients who have been provided
with implant-supported restorations
on a regular basis. The following
aspects are recommended for the
clinical routine:
• When implant treatment is consid-
ered, patients should be informed
on the risks for biological compli-
cations (peri-implant diseases) and
the need for preventive care.
• An individual risk assessment
including systemic and local risk
indicators should be performed
and modifiable risk factors, such
as residual increased probing
pocket depth in the remaining
dentition or smoking, should be
eliminated. Hence, treatment of
periodontal disease aiming for
elimination of residual pockets
with bleeding on probing and
smoking cessation should precede
implant placement
• The correct fit of implant compo-
nents and the suprastructure has
to be ensured to avoid additional
niches for biofilm adherence. If
cemented implant restorations
have been selected, the restoration
margins should be located at the
mucosal margin to allow meticu-
lous removal of excess cement.
• Clinicians have to be aware that
implant placement at a submuco-
sal level (to hide crown margins)
may carry a higher risk for peri-
implant diseases.
• To facilitate personal oral
hygiene, clinicians should con-
sider having keratinized attached
and unmovable tissue surround-
ing the transmucosal implant
portion already during implant
placement (for one-stage implant
placement) or during abutment
connection (for two-stage implant
placement).
• Since infection control is essential
in the prevention of peri-implant
diseases, patients have to be
instructed on their personal oral
hygiene with regular monitoring
and reinforcement.
• Implant position should be
selected and suprastructures
should be designed in a way
facilitating sufficient access for
regular diagnosis by probing as
well as for personal and profes-
sional oral hygiene measures.
• Professional supportive care
should be established according
to the individual needs of the
patient (e.g. 3-, 6- or 12-month
recall intervals) and their compli-
ance has to be confirmed.
• Particularly in patients with a
history of treated aggressive
periodontitis indicating an incre-
ased susceptibility for periodontal
and peri-implant diseases, shorter
recall intervals should be
considered.
• During recall peri-implant tissues
must be regularly examined
including probing assessments
with special emphasis on bleeding
on probing.
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Clinical relevance
Background: In the absence of estab-
lished and predictable treatment
concepts for peri-implantitis, pre-
vention is of uppermost importance.
Principal findings: Peri-implant dis-
eases are highly prevalent. Bleeding
on probing can distinguish between
peri-implant health and disease.
Plaque accumulation is an aetiologi-
cal factor and smoking and excess
cement are modifiable risk indictors
for the development of peri-implant
mucositis. Both patient- and profes-
sionally administered mechanical
measures for plaque removal are
effective for the reduction of inflam-
mation in the peri-implant mucosa.
Conclusions: Successful manage-
ment of peri-implant mucositis
should comprise proper diagnosis
by regular probing as well as effec-
tive self-performed and supportive
professional plaque removal.
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